ArticleMicrobial cell factories2026
A combined strategy for high-efficiency expression of alkaline protease PrtA in Komagataella phaffii (syn. Pichia pastoris).
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMicrobial serine proteases are valuable for industrial applications due to broad substrate specificity and stability. However, heterologous overexpression in microbial hosts is often limited by cytotoxicity and poor secretion. This study developed an integrated strategy combining protein engineering and signal peptide optimization to enhance extracellular production of PrtA—a key acid-stable alkaline serine protease—in Komagataella phaffii.
resultsDirected evolution generated the Q245K variant, showing 1.35-fold higher extracellular expression than wild-type PrtA. A machine learning model, MPEPE (Mutation Predictor for Enhanced Protein Expression), was used to identify critical residues involved in protein secretion; saturation mutagenesis at the top-predicted site generated the I342D mutant with 1.48-fold improved productivity. The double mutant PrtA-Q245K/I342D achieved synergistic enhancement (1.84-fold higher secretion) without altering enzymatic properties. Evaluation of nine signal peptides revealed that serum albumin, α-factor (without pro-region), and PrtA’s native signal peptides each doubled the combinatorial mutant’s secretion, yielding 4.98-fold higher expression than the wild-type. In contrast, α-factor pro-region inclusion drastically reduced yields. In a 15-L fed-batch bioreactor, the optimized strain produced PrtA-Q245K/I342D at 4807.5 U/mL, equivalent to 1.5 g/L protein.
conclusionsThe combined approach of directed evolution, machine learning-guided mutagenesis, and signal peptide engineering significantly boosted PrtA secretion while maintaining functional integrity. This strategy demonstrates strong potential for scalable industrial production of challenging heterologous proteases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.